Skip to content
Home/Companies/Pharma/Provell Pharmaceuticals

Provell Pharmaceuticals

Pharma·US·Exited 2025·Held 12yr
Entry
2013
Hold
12yr
Exit
2025

Who owns Provell Pharmaceuticals?

Provell Pharmaceuticals was owned by Flerie through Flerie Invest (2011 vintage) from 2013 to 2025.

Hand-verified · updated 2026-08-17

Flerie
Investor
Flerie
Flerie Invest · 2011 · Life Sciences VC

Key facts

HQUnited States
SectorPharma
StatusAcquired
Exit Type
–
Buyer
–
MOIC
–
Exit Year
2025

More from Flerie Invest

Other portfolio companies in the same fund.

Frontier Biosolutions
Active
PharmaGermany· 2023
Mendus
Active
BiotechSweden· 2023
A3P Biomedical
Exited 2025
BiotechSweden· 2022
Alder Therapeutics
Active
BiotechSweden· 2022
AnaCardio
Active
BiotechSweden· 2022
Bohus Biotech
Active
PharmaSweden· 2022

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Advantice Health
Advantice Health
Active
TA AssociatesUS
Alvogen
Alvogen
Active
CVC Capital Partners
CANbridge
CANbridge
Active
General AtlanticChina
Ceva
Ceva
Exited 2025
iXO Private EquityFrance
to
curia
curia
Active
The Carlyle GroupUS
Ideal Cures Pvt. Ltd.
Ideal Cures Pvt. Ltd.
Active
TA AssociatesIndia
Track Provell Pharmaceuticals

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Provell Pharmaceuticals?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Provell Pharmaceuticals.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue